Clinical trials: Central Nervous System
Sarcopenia
Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in patients with sarcopenia.
- Trial name
- NCT01963598
- Testing
- REGN1033 (SAR391786)
- Where
- 43 sites in United States, France and 2 more
- Volunteers
- 253 people
- Sponsor
- Regeneron Pharmaceuticals
Ischemic Stroke
Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome
Post intensive care syndrome (PIC syndrome) is an important problem in modern intensive care strategy. Understanding the mechanisms of PIC syndrome helps prevent it in patients with respiratory, neuromuscular transmission, and…
- Trial name
- NCT06735898
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Parkinson's Disease
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
The study had three distinct parts and is described as follows: Part 1: To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD To evaluate the utility of…
- Trial name
- NCT01411137
- Testing
- IPX066
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Impax Laboratories, LLC
Essential Tremor
A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
This study will look at the ability of ST101 to treat symptoms in subjects with Essential Tremor. This study will also examine the safety and tolerability of the drug.
- Trial name
- NCT01332695
- Testing
- ST101
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sonexa Therapeutics, Inc.
Dementias With Lewy Bodies
A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
The primary objective of the study is to achieve mass balance recovery of [14C]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
- Trial name
- NCT04023877
- Testing
- E2027
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Urea Cycle Disorders
Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)
The aim of the study is to assess the efficacy of HepaStem treatment in paediatric patients suffering from urea cycle disorders.
- Trial name
- NCT02489292
- Testing
- HepaStem
- Where
- 6 sites in Belgium, France and 2 more
- Volunteers
- 5 people
- Sponsor
- Cellaion SA
Epilepsy, Epilepsy, Focal
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
The purpose of this study is to demonstrate that RWJ-333369 is safe and effective as add-on treatment of partial onset seizures.
- Conditions
- Epilepsy, Epilepsy, Focal, Seizure Disorder, Complex Partial Seizures
- Trial name
- NCT00433667
- Testing
- RWJ-333369
- Volunteers
- 563 people
- Sponsor
- SK Life Science, Inc.
Epilepsy
Bioequivalence and Food Effect of 250mg of Lamotrigine XR
This study intends to demonstrate bioequivalence and lack of food effect on 250mg lamotrigine XR in healthy male and female volunteers
- Trial name
- NCT00605371
- Testing
- Lamotrigine tablet, Lamotrigine caplet
- Where
- United States
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients
The purpose of this study is to determine whether the gastric retentive Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) is more effective than the commercially available immediate release Carbidopa/Levodopa in reducing motor…
- Trial name
- Accordance (NCT02605434)
- Testing
- Accordion Pill™ Carbidopa/Levodopa, Sinemet®
- Where
- 97 sites in United States, Bulgaria and 8 more
- Volunteers
- 420 people
- Sponsor
- Intec Pharma Ltd.
Healthy Participants, Alzheimer Disease
A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers
This study is the first clinical trial involving study drug KS101. The goal of this clinical trial is to investigate whether KS101 is safe, whether it causes side effects, and how KS101 is broken down in the body, in healthy…
- Conditions
- Healthy Participants, Alzheimer Disease, Chronic Kidney Disease
- Trial name
- NCT07143331
- Testing
- Part 1 KS101, Part 2 with Food, Part 2 without food
- Where
- Australia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Klotho Sciences Australia Pty Ltd.
Endometrial Cancer
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
- Trial name
- NCT06463028
- Testing
- Sapanisertib, Serabelisib, Paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- Faeth Therapeutics
Spinal Cord Injury, Safety
Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial
This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury
- Conditions
- Spinal Cord Injury, Safety, Clinical Trials, Efficacy
- Trial name
- NCT06976229
- Testing
- Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset
Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients.
- Trial name
- NCT07741045
- Testing
- TJ0113 200mg, TJ0113 400mg
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
Sensorimotor Gait Disorder, Neurologic Ambulation Disorder
Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop
The objective of this study is to determine the effectiveness of the NESS L300 (L300) in improving gait parameters, function, and quality of life among stroke subjects (greater than or equal to 3 months post stroke)with drop foot.
- Conditions
- Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis
- Trial name
- L300 (NCT01138995)
- Testing
- Ness L300, Ankle-foot orthosis
- Where
- 11 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bioness Inc
Hypercholesterolemia, Coronary Heart Disease
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, Cerebrovascular Accident
- Trial name
- HEROS (NCT00660764)
- Testing
- Rosuvastatin
- Sponsor
- AstraZeneca
Parkinson's Disease
A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.
- Trial name
- NCT02337764
- Testing
- TVP-1012 1mg
- Where
- 24 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Takeda
Hereditary Ataxia
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia
The Hereditary Ataxias are a group of genetic disorders characterized by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements.
- Trial name
- NCT01360164
- Testing
- human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Pompe Disease
Extension Study for Patients Who Have Participated in a BMN 701 Study
This is a Phase 2 open-label, multiple dose study of BMN 701 administered by IV infusion every 2 weeks (qow) to patients with late-onset Pompe disease.
- Trial name
- NCT01435772
- Testing
- BMN 701
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 21 people
- Sponsor
- BioMarin Pharmaceutical
Recurrent Glioblastoma Multiforme
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody.
- Trial name
- NCT00509301
- Testing
- 131-I-chTNT-1/B MAB
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Peregrine Pharmaceuticals
Parkinson Disease
Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease
Study to document pramipexole dosing during monotherapy, occurrence of fluctuations and dyskinesias, dose increases after deterioration of Parkinson's disease (PD) symptoms, assessment of the reasons for add-on treatment with…
- Trial name
- NCT02248181
- Testing
- Pramipexole
- Volunteers
- 442 people
- Sponsor
- Boehringer Ingelheim